A single molecule that activates both GLP-1 and amylin receptors at the same time. Being investigated for obesity, as a weekly injection and as a pill.
Regulatory status
In clinical trials
Family
Unimolecular GLP-1 and amylin receptor agonist
Scientific evidence
Low-moderate
Number of findings
1
Where it acts
Digestive and weight · Hormones and metabolism
Also known as
amycretin, NNC0487-0111
Regulatory status
FDA (US): Not approved (in phase 3 for weight management).
EMA (EU): Not approved.
Dose
There is no established dose in humans. In the phase 1b/2a trial, weekly subcutaneous doses escalated up to 1.25, 5, 20, or 60 mg were used (Lancet 2025).
Safety
Digestive effects (nausea, vomiting, diarrhea) were the most frequent, mostly mild or moderate. Many dropouts in the trial, mostly not attributed to adverse effects. Use only in clinical trials or research, under medical supervision; buying it is not recommended.
Effect by goal · level of evidence
Weight loss with the injectable version
improvesLow-moderateRCT (AA)in people
−24% weight
Phase 1b/2a trial (125 adults): after 36 weeks, weight loss was 22.0% with 20 mg and 24.3% with 60 mg, vs +1.9% and −1.1% with placebo. With low doses and shorter treatments, weight loss was 9.7% to 16.2%.
Combines in a single molecule the action of GLP-1 (more satiety, better glucose control, slower gastric emptying) and that of amylin (satiety through a different brain pathway). The sum of both signals reduces appetite and intake more than either one alone.
What the evidence says
In people
Weight loss with the injectable version. Phase 1b/2a trial (125 adults): after 36 weeks, weight loss was 22.0% with 20 mg and 24.3% with 60 mg, vs +1.9% and −1.1% with placebo. With low doses and shorter treatments, weight loss was 9.7% to 16.2%. PubMed 40550231